Doxycycline-Induced Autoimmune Hepatitis
- PMID: 32821768
- PMCID: PMC7423905
- DOI: 10.14309/crj.0000000000000440
Doxycycline-Induced Autoimmune Hepatitis
Abstract
Doxycycline and minocycline are tetracyclines with the potential to cause hepatoxicity. Although autoimmune-like hepatitis from minocycline is well-described, doxycycline-induced autoimmune hepatitis (DIAH) has only been described once. We report a rare case of DIAH with elevated liver enzymes over 5 times the normal upper limit, elevated immunoglobulin G, and high titers of antismooth muscle antibody and antinuclear antibody. By stopping doxycycline, our patient's liver enzymes normalized and immunoglobulin G and autoantibody titers rapidly downtrended. As long-term doxycycline therapy becomes more prevalent to treat acne vulgaris and other skin conditions, DIAH may become more prevalent and recognized.
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Figures



References
-
- Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–76. - PubMed
-
- Mann MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213. - PubMed
-
- Bjornsson E, Talwalker J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51:2040–8. - PubMed
-
- Fakhreddine A, Frenette C. A cautionary report of doxycycline-induced autoimmune hepatitis. Hepatology. 2020;71:1515–7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials